Private label OTC maker building new South Carolina plant, to add 450 jobs

New York-based PL Developments will build a second manufacturing site in South Carolina.

PL Developments, a specialist of private label OTC products, will build a second manufacturing site in South Carolina, adding up to 450 jobs when it is complete.

The Westbury, New York, company will invest about $45 million in the new logistics and manufacturing center in Piedmont, South Carolina, with the help of a $750,000 grant from Greenville County for site improvements. This will be the company’s sixth U.S. site.

The logistics operations are slated to be up and operating next year and the product manufacturing is expected be online in 2018.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Opening a sixth production site has been a strategic objective for nearly two years,” PL Developments President Evan Singer said in a statement. “Longer term, the company has several growth initiatives which will be made feasible through the investments made at the site.”

PL Developments acquired its first site in the south in 2013 when the solid-dose maker of OTC products bought South Carolina-based Aaron Industries, a liquid product specialist. At the time, PL execs said the company’s compelling proposition was that it would be a strong competitor to market-dominant Perrigo.

PL Development built its expertise in packaging and distribution to meet the just-in-time requirements of a long list of large-box retail chain customers like Walmart, Costco, Walgreen's, CVS, Target, Dollar General and others. The company now produces about 450 products.

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.